Advancing Toward the UNAIDS 95‑95‑95 Targets in Sierra Leone: A Narrative Review of Progress, Persistent Gaps, and Policy Priorities

Read full text Summarise with VIRAT
Authors: Augustus Osborne, Ibrahim Franklyn Kamara, Sulaiman Lakoh, Mariama Mustapha, Alren O. Vandy, Morie Vandi, Sia Morenike Tengbe, Osman A. Sankoh
Cited by: 0
References: 1

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Sierra Leone, with a low adult HIV prevalence (~1.6–1.7%), faces uneven progress toward the UNAIDS 95‑95‑95 targets, with significant gaps in diagnosis, viral load (VL) coverage, and key population reach. Methods: A narrative review (January 2013–June 2024; final search 30 June 2024) synthesized national reports and peer‑reviewed articles on Sierra Leone’s HIV cascade and systemic determinants. Data focused on diagnosis, treatment, suppression, and cross‑cutting issues (e.g., stigma, supply chain). Results: In 2023, of an estimated 82,000 people living with HIV (PLHIV), 80% (65,600) were diagnosed. Of those diagnosed, 87% (57,072) were on antiretroviral therapy (ART), and 44% of those on ART (25,112) were virally suppressed. VL testing covered 68% of ART patients (38,812), suggesting incomplete coverage may underestimate true population‑level suppression if untested patients are less likely to be suppressed. Key bottlenecks include limited VL platforms, commodity stockouts of antiretrovirals, stigma (especially for female sex workers), adolescent retention gaps, absent drug resistance surveillance, fragmented data systems, and donor‑dependent financing. Conclusions: Progress is tangible but fragile. Prioritizing detection (first 95) through scaled testing, alongside VL network strengthening, differentiated service delivery (e.g., six‑month multi‑month dispensing), stigma monitoring, drug resistance surveillance, and sustainable financing roadmaps, is essential. Targeted research on implementation and cost‑effectiveness will support equitable attainment of HIV 2030 goals.

Fields of Study & Subjects

HIV/AIDS Research and Interventions HIV/AIDS Impact and Responses HIV Drug Use Sexual Risk

Publication details

Journal / source
Annals of Global Health
Volume
92
Issue
1
Pages
27–27
Publication date
25 March 2026
Language
EN